4523 JP3160400002

Report

Delayed Japan Exchange - 02:00 2022-07-01 am EDT
5691.00	JPY		-0.59%

06/24	Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases	AQ
06/22	PRESSWIRE GLOBAL NEWS DISTRIBUTION : ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application	AQ
06/22	Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal	AQ

Summary

Quotes 5-day view Delayed Quote.

Delayed Japan Exchange

06/27/2022	06/28/2022	06/29/2022	06/30/2022	07/01/2022	Date
5620(c)	5712(c)	5800(c)	5725(c)	5691(c)	Last
851 000	813 000	1 479 700	1 156 000	783 500	Volume
+1.06%	+1.64%	+1.54%	-1.29%	-0.59%	Change

More quotes

Estimated financial data (e)

Sales 2022	734 B 5 430 M 5 430 M
Net income 2022	56 199 M 416 M 416 M
Net cash position 2022	143 B 1 060 M 1 060 M
P/E ratio 2022	27,5x
Yield 2022	2,81%

Sales 2023	704 B 5 203 M 5 203 M
Net income 2023	50 890 M 376 M 376 M
Net cash position 2023	226 B 1 671 M 1 671 M
P/E ratio 2023	31,6x
Yield 2023	2,83%

Capitalization	1 632 B 12 070 M 12 070 M
EV / Sales 2022	2,03x
EV / Sales 2023	2,00x
Nbr of Employees	11 322
Free-Float	87,9%

More Financials

Company

Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (87.7%): prescribed drugs, health products, etc.; - other (12.3%): food additives, chemical products, etc. Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).

Sector

Pharmaceuticals

Calendar

08/03

Earnings Release

More about the company

Ratings of Eisai Co., Ltd.

Trading Rating :

Investor Rating :

ESG Refinitiv :

A-

More Ratings

All news about EISAI CO., LTD.

06/24	Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglect..	AQ
06/22	PRESSWIRE GLOBAL NEWS DISTRIBUTION : ProMIS Neurosciences Announces Filing of Form 10 Regi..	AQ
06/22	Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed ..	AQ
06/07	EISAI : Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the..	PU
06/06	Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 202..	AQ
06/05	EISAI PRESENTS NEW FINDINGS FOR ANTI : #5513)Poster Presentation Features Analyses Based o..	PU
06/03	Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting	AQ
05/30	Eisai to Acquire Remaining 15% of Consolidated Unit	MT
05/30	EISAI : Announcement of a Summary Share Exchange (kan'i kabushiki kokan) to Make Sunplanet..	PU
05/27	Eisai Contributes to the Science of Cancer Medicine at ASCO 2022	AQ
05/27	EISAI : MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formula..	AQ
05/23	MARKETSCREENER'S WORLD PRESS REVIEW : May 23, 2022
05/20	EISAI : “MOVICOL® HD” LaunchedA New Dosage Form Added to Polyethylene Glycol C..	PU
05/19	Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritora..	CI
05/16	Eisai Reiterates Year-end Dividend on Higher FY22 Profit, Revenue as Global Brands Cont..	MT

More news

News in other languages on EISAI CO., LTD.

05/23	BROADCOM VISE VMWARE, AIRBUS ÉPARGNE : la revue de presse du lundi 23 mai 2022
05/19	La Coalition mondiale pour la recherche adaptative annonce l'arrêt de l'évaluation d'Er..
05/16	Eisai réitère son dividende de fin d'année en raison de l'augmentation du bénéfice et d..
05/12	Nitto Denko Corporation fournit des prévisions de bénéfices consolidés pour l'année fis..
05/12	Eisai Co., Ltd. annonce le versement d'un dividende de fin d'année pour l'exercice clos..

More news

Analyst Recommendations on EISAI CO., LTD.

2020	Nikkei hits over 2-year high on Wall Street boost, focus on final U.S. election tally	RE
2020	Biogen Alzheimer's drug closer to approval with U.S. FDA staff backing, shares jump 40%	RE
2019	Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value	RE

More recommendations

Provided by Scoopnest.com

Analysis

Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm